Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial
Targeted Oncology · 2026-07 · 21 (4) · 549-557
DOI: 10.1007/s11523-026-01223-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Targeted Oncology, online erschienen am 20.05.2026. Verfasst von Yu Sunakawa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan. y.suna082…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Camptothecin, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Eli Lilly Japan.
Abstract (Originalsprache)
BACKGROUND: Second-line FOLFIRI plus ramucirumab (RAM) is one of standard treatments for metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy in RAS wild-type tumors. However, biomarkers for RAM efficacy remain unclear. OBJECTIVE: We conducted a translational analysis to evaluate the association of plasma biomarkers, including angiogenesis-related factors (AFs) and RAS mutations in circulating tumor DNA (ctDNA), with clinical outcomes. METHODS: This biomarker study was embedded within the JACCRO CC-16 trial, which enrolled patients with mCRC with RAS wild-type tumors receiving FOLFIRI plus RAM after anti-EGFR therapy. Plasma samples were collected at baseline, day 15, and post-treatment. RAS status in ctDNA was analyzed using BEAMing digital PCR; AFs were assessed using Luminex multiplex assay. Associations with progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analyzed. RESULTS: Among 41 evaluable patients with RAS wild-type tumors, RAS mutations were detected in ctDNA at pretreatment in 44%. Patients without RAS mutations had significantly longer OS (28.1 versus 14.8 months; HR 0.30, p = 0.0008) and higher ORR (14.3% versus 5.6%). Elevated baseline interleukin-8 (IL-8) was associated with poorer OS (16.5 versus 32.2 months; HR 1.99, p = 0.049). IL-8 levels were significantly higher in patients with RAS mutations. CONCLUSION: RAS mutations in ctDNA and elevated IL-8 levels prior to second-line FOLFIRI plus RAM were associated with worse prognosis in mCRC. Moreover, our study demonstrated a significant association between RAS mutations and high IL-8 levels in this setting, suggesting a potential molecular-inflammatory interplay that contributes to resistance to VEGFR2 blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan. y.suna0825@gmail.com.
- Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
- Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
- Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.
- Department of Gastroenterological Surgery, Sendai City Medical Center Sendai Open Hospital, Sendai, Japan.
- Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Förderung
- Eli Lilly Japan
Zitieren
APA
Sunakawa, Y., Yasui, H., Shiozawa, M., Takeda, H., Akazawa, N., Sagawa, T., Shiraishi, K., Kyogoku, T., Mine, T., Yuasa, Y., Watanabe, T., Kinjo, T., Okita, Y., Okuyama, H., Yuki, S., Miyakawa, K., Kobara, A., Yanaka, S., Abe, Y., …, & Tsuji, A. (2026). Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial. Targeted Oncology, 21(4), 549-557. https://doi.org/10.1007/s11523-026-01223-2
Vancouver
Sunakawa Y, Yasui H, Shiozawa M, Takeda H, Akazawa N, Sagawa T, et al. Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial. Targeted Oncology. 2026;21(4):549-557. doi:10.1007/s11523-026-01223-2
BibTeX
@article{Sunakawa2026,
author = {Sunakawa, Yu and Yasui, Hisateru and Shiozawa, Manabu and Takeda, Hiroyuki and Akazawa, Naoya and Sagawa, Tamotsu and Shiraishi, Kazuhiro and Kyogoku, Takahisa and Mine, Takashi and Yuasa, Yasuhiro and Watanabe, Takanori and Kinjo, Tatsuya and Okita, Yoshihiro and Okuyama, Hiroyuki and Yuki, Satoshi and Miyakawa, Koki and Kobara, Ayana and Yanaka, Shoko and Abe, Yukiko and Ichikawa, Wataru and Fujii, Masashi and Tsuji, Akihito},
title = {Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial},
journal = {Targeted Oncology},
year = {2026},
volume = {21},
number = {4},
pages = {549--557},
doi = {10.1007/s11523-026-01223-2}
}
EUVIMED